Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    June 2025
  1. ZHANG J, Wang S, Li T, Liu X, et al
    RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis.
    J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093.
    PubMed    


    May 2025
  2. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed     Abstract available


    March 2025
  3. ZHOU P, Cui J, Sun R, Liu X, et al
    RE: Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025 Mar 27:djaf081. doi: 10.1093.
    PubMed    


  4. MILDER CM, Cahoon EK, Schonfeld SJ, Preston DL, et al
    Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiologic technologists.
    J Natl Cancer Inst. 2025 Mar 20:djaf064. doi: 10.1093.
    PubMed     Abstract available


  5. NOGUEIRA LM, Yabroff KR, Yates E, Shultz JM, et al
    Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery.
    J Natl Cancer Inst. 2025 Mar 11:djaf040. doi: 10.1093.
    PubMed     Abstract available


    February 2025
  6. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available


    January 2025
  7. KANAYA N, Seddiq W, Chen KS, Kajiwara Y, et al
    Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis.
    J Natl Cancer Inst. 2025 Jan 22:djaf006. doi: 10.1093.
    PubMed     Abstract available


  8. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    PubMed     Abstract available


  9. TUMINELLO S, Turner WM, Untalan M, Ivic-Pavlicic T, et al
    Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025;117:112-119.
    PubMed     Abstract available


    November 2024
  10. GOMEZ SL, DeRouen M, Chen MS Jr, Wakelee H, et al
    Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.
    J Natl Cancer Inst. 2024 Nov 20:djae299. doi: 10.1093.
    PubMed     Abstract available


  11. SMITH RJ JR, Zollo R, Kalvapudi S, Vedire Y, et al
    Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.
    J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093.
    PubMed     Abstract available


    October 2024
  12. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available


  13. CHU X, Tian W, Ning J, Zhou R, et al
    Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis.
    J Natl Cancer Inst. 2024;116:1571-1586.
    PubMed     Abstract available


    September 2024
  14. PROSPER AE, Lin Y, Aberle DR
    Lung cancer screening with low-dose computed tomography-where do we go from here?
    J Natl Cancer Inst. 2024 Sep 16:djae197. doi: 10.1093.
    PubMed    


    August 2024
  15. LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al
    Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093.
    PubMed     Abstract available


  16. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available


    June 2024
  17. ZHANG EY, Cheung LC, Katki HA, Graubard BI, et al
    The risk and benefit profiles of US eligible lung cancer screening attendees vs. non-attendees.
    J Natl Cancer Inst. 2024 Jun 27:djae148. doi: 10.1093.
    PubMed     Abstract available


  18. HENDERSON LM, Durham DD, Gruden J, Pritchard M, et al
    Comparing characteristics of individuals screened for lung cancer with 2021 versus 2013 USPSTF recommendations.
    J Natl Cancer Inst. 2024 Jun 24:djae141. doi: 10.1093.
    PubMed     Abstract available


  19. WU X, Zhang B
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 8:djae130. doi: 10.1093.
    PubMed    


  20. TAKI T, Ishii G
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 7:djae131. doi: 10.1093.
    PubMed    


  21. SCHUZ J, Kovalevskiy E, Olsson A, Moissonnier M, et al
    Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study).
    J Natl Cancer Inst. 2024;116:866-875.
    PubMed     Abstract available


  22. UPRETY D, Seaton R, Hadid T, Mamdani H, et al
    Racial and socioeconomic disparities in survival among patients with metastatic Non-Small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093.
    PubMed     Abstract available


    March 2024
  23. FUCITO LM, Palmer AM, Baldassarri SR
    A new perspective on mitigating lung cancer risks through smoking cessation and reduction.
    J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093.
    PubMed    


  24. NAGASAKI Y, Taki T, Nomura K, Tane K, et al
    Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  25. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    PubMed     Abstract available


  26. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    PubMed     Abstract available


    January 2024
  27. GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al
    Changes in smoking use and subsequent lung cancer risk in the ATBC study.
    J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093.
    PubMed     Abstract available


    December 2023
  28. SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al
    Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the U.S., 1991-2018.
    J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093.
    PubMed     Abstract available


  29. BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al
    Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
    J Natl Cancer Inst. 2023;115:1515-1525.
    PubMed     Abstract available


  30. ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al
    Global epidemiologic patterns of oropharyngeal cancer incidence trends.
    J Natl Cancer Inst. 2023;115:1544-1554.
    PubMed     Abstract available


    November 2023
  31. LEHRER S, Rheinstein PH
    Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
    J Natl Cancer Inst. 2023;115:1427-1428.
    PubMed    


  32. LU K, Wang HC, Tu YC, Chang CC, et al
    Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
    J Natl Cancer Inst. 2023;115:1383-1391.
    PubMed     Abstract available


  33. EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al
    Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    J Natl Cancer Inst. 2023;115:1404-1419.
    PubMed     Abstract available


    September 2023
  34. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
    Circulating proteome for pulmonary nodule malignancy.
    J Natl Cancer Inst. 2023;115:1060-1070.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.